IP Verse

Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab

EP2766040

F. HOFFMANN-LA ROCHE AG
Application Number
EP12778010A
Filing Date
Oct 11, 2012
Status
Revoked
Jun 10, 2022
Grant Date
May 15, 2019
External Links
Slate, Register

Biblio Summary

The patent EP2766040B1 was granted on May 15, 2019 by F. Hoffmann-La Roche Ag The patent is currently Revoked.

Oppositions Filed by other Companies on the Patent

The table below shows 9 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

DR. REDDY'S LABORATORIES LIMITEDFeb 17, 2020ADMISSIBLE
LEDL, ANDREASFeb 17, 2020ADMISSIBLE
EUROPEAN OPPOSITIONS LIMITEDFeb 14, 2020ADMISSIBLE
J A KEMP LLPFeb 14, 2020ADMISSIBLE
POHLMAN, SANDRA M.Feb 14, 2020ADMISSIBLE
ROTH, CARLAFeb 14, 2020ADMISSIBLE
GILL JENNINGS & EVERY LLPFeb 13, 2020ADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEFeb 13, 2020ADMISSIBLE
DR. H. ULRICH DORRIESFeb 13, 2020WITHDRAWN

More Opposed Patents of F. Hoffmann-La Roche Ag

The table below shows the patents of F. Hoffmann-La Roche Ag that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3257564Overload And Elute ChromatographyMay 29, 20241
EP3294770Therapeutic And Diagnostic Methods For CancerMar 20, 20242
EP3998095Device For Sustained Delivery Of A Therapeutic FluidJan 31, 20241

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents